Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial